Literature DB >> 8035510

Sequence-specific binding of the influenza virus RNA polymerase to sequences located at the 5' ends of the viral RNAs.

L S Tiley1, M Hagen, J T Matthews, M Krystal.   

Abstract

The enzymatic activity of recombinant influenza virus RNA polymerase is strictly dependent on the addition of a template RNA containing 5' and 3' viral sequences. Here we report the analysis of the binding specificity and physical characterization of the complex by using gel shift, modification interference, and density gradient techniques. The 13S complex binds specifically to short synthetic RNAs that mimic the partially double stranded panhandle structures found at the termini of both viral RNA and cRNA. The polymerase will also bind independently to the single-stranded 5' or 3' ends of viral RNA. It binds most strongly to specific sequences within the 5' end but is unable to bind these sequences in the context of a completely double stranded structure. Modification interference analysis identified the short sequence motifs at the 5' ends of the viral RNA and cRNA templates that are critical for binding.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035510      PMCID: PMC236454     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Transcription of the influenza virus genome.

Authors:  A J Hay; B Lomniczi; A R Bellamy; J J Skehel
Journal:  Virology       Date:  1977-12       Impact factor: 3.616

2.  Direct chemical method for sequencing RNA.

Authors:  D A Peattie
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

3.  Sequence-specific interaction of R17 coat protein with its ribonucleic acid binding site.

Authors:  J Carey; V Cameron; P L de Haseth; O C Uhlenbeck
Journal:  Biochemistry       Date:  1983-05-24       Impact factor: 3.162

4.  Characterization of influenza virus RNA complete transcripts.

Authors:  A J Hay; J J Skehel; J McCauley
Journal:  Virology       Date:  1982-01-30       Impact factor: 3.616

5.  Polyadenylation sites for influenza virus mRNA.

Authors:  J S Robertson; M Schubert; R A Lazzarini
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

6.  5' and 3' terminal nucleotide sequences of the RNA genome segments of influenza virus.

Authors:  J S Robertson
Journal:  Nucleic Acids Res       Date:  1979-08-24       Impact factor: 16.971

7.  The 3' and 5'-terminal sequences of influenza A, B and C virus RNA segments are highly conserved and show partial inverted complementarity.

Authors:  U Desselberger; V R Racaniello; J J Zazra; P Palese
Journal:  Gene       Date:  1980-02       Impact factor: 3.688

8.  Influenza virus messenger RNAs are incomplete transcripts of the genome RNAs.

Authors:  A J Hay; G Abraham; J J Skehel; J C Smith; P Fellner
Journal:  Nucleic Acids Res       Date:  1977-12       Impact factor: 16.971

9.  A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription.

Authors:  S J Plotch; M Bouloy; I Ulmanen; R M Krug
Journal:  Cell       Date:  1981-03       Impact factor: 41.582

10.  Cap and internal nucleotides of reovirus mRNA primers are incorporated into influenza viral complementary RNA during transcription in vitro.

Authors:  M Bouloy; M A Morgan; A J Shatkin; R M Krug
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

View more
  94 in total

1.  Polyuridylated mRNA synthesized by a recombinant influenza virus is defective in nuclear export.

Authors:  L L Poon; E Fodor; G G Brownlee
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Mutagenic analysis of the 5' arm of the influenza A virus virion RNA promoter defines the sequence requirements for endonuclease activity.

Authors:  M B Leahy; D C Pritlove; L L Poon; G G Brownlee
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Direct evidence that the poly(A) tail of influenza A virus mRNA is synthesized by reiterative copying of a U track in the virion RNA template.

Authors:  L L Poon; D C Pritlove; E Fodor; G G Brownlee
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

4.  Influenza A virus RNA polymerase has the ability to stutter at the polyadenylation site of a viral RNA template during RNA replication.

Authors:  H Zheng; H A Lee; P Palese; A García-Sastre
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Definition of the minimal viral components required for the initiation of unprimed RNA synthesis by influenza virus RNA polymerase.

Authors:  M T Michael Lee; Konrad Bishop; Liz Medcalf; Debra Elton; Paul Digard; Laurence Tiley
Journal:  Nucleic Acids Res       Date:  2002-01-15       Impact factor: 16.971

6.  Differential activation of influenza A virus endonuclease activity is dependent on multiple sequence differences between the virion RNA and cRNA promoters.

Authors:  Michael B Leahy; Giuseppe Zecchin; George G Brownlee
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

7.  Structural features of an influenza virus promoter and their implications for viral RNA synthesis.

Authors:  S H Bae; H K Cheong; J H Lee; C Cheong; M Kainosho; B S Choi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

8.  Hairpin loop structure in the 3' arm of the influenza A virus virion RNA promoter is required for endonuclease activity.

Authors:  M B Leahy; H C Dobbyn; G G Brownlee
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

9.  Activation of influenza virus RNA polymerase by the 5' and 3' terminal duplex of genomic RNA.

Authors:  M-T Michael Lee; Klaus Klumpp; Paul Digard; Laurence Tiley
Journal:  Nucleic Acids Res       Date:  2003-03-15       Impact factor: 16.971

10.  A single amino acid mutation in the PA subunit of the influenza virus RNA polymerase promotes the generation of defective interfering RNAs.

Authors:  Ervin Fodor; Louise J Mingay; Mandy Crow; Tao Deng; George G Brownlee
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.